CARF and neoplasm: To comprehensively understand the specific role of CARF in different tumors, we conducted a pan‐cancer‐level systematic analysis with the Cancer Genome Atlas Program (TCGA) database (Figure1A), which integrated data from approximately 11000 patient samples from 26 different cancer types.[23] We determined the optimal cutoff for CARF expression in patient samples of each cancer type using the minimum p‐value approach and classified them into high and low groups, and summarized the percentage and number of patients of each tumor type (Table S1, Supporting Information).